Evaluation of molecular changes in the mucous membrane close to the resection margin after surgical treatment for gastric cancer

Objective: Secretion of the changes characterizing genetic instability of the gastric mucosa when having esophagus cancer.Methods: 64 patients having esophagus cancer (main group) and 50 patients having gallstone disease were examined. They were undergoing treatment in the hospital No. 1 of the I.M. Sechenov First Moscow State Medical University. In all cases molecular tumor markers in the gastric mucosa after operation and biopsy were examined.Results: Esophagus cancer turned out to be characterized by high frequency of RASSF1А and MLH1 genes methylation and high hTERT, MMP7 and BIRC5 genes expression, and also by high telomerase activity. There was also high frequency of TUSC3, CDH1 and DAPK genes methylation inside gastric mucosa approached to the edge of resection.Conclusions: The study of the frequency of TUSC3, CDH1, DAPK, RASSF1А and MLH1 genes methylation and telomerase activity can be used as clinical markers defining changes in gastric mucosa after its resection concerning cancer.

Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.